Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Amerigen Pharmaceuticals has entered an agreement with the Shanghai Fosun Omni Pharmaceutical to develop generic oral controlled release products.
Subscribe to our email newsletter
As per the collaboration, Fosun Omni will use its expertise in formulation to develop products for Amerigen to commercialize in the US and other territories.
Fosun Omni is said to have received an up-front fee with respect to the first product and is entitled to additional product-specific development milestones and royalties on any commercialized products.
Amerigen chief business officer Jonathan Embleton said the agreement would reinforce its efforts to establish a range of differentiated, high value generic pharmaceuticals.